SciClone – About the Company
SciClone (NasdaqGS: SCLN) is a profitable specialty pharmaceutical company that develops and commercializes products in the growing Chinese market. The Company’s lead product and main source of revenue is Zadaxin (thymalfasin), an immune system enhancer used in the treatment of cancer and hepatitis. Zadaxin sales increased by an estimated 16% from 2014 to 2015, and have the potential to continue growing as the Chinese pharmaceutical market expands. In addition, DC Bead for liver cancer patients was launched in 2015 and efforts are underway to educate physicians on this product. SciClone also has 6 products that is promotes for pharmaceutical companies, and a pipeline of 7 in-licensed candidates in various stages of clinical development that could provide sustainable long-term revenue.